1154 / 2351
5/30/16
1
Management of oropharyngeal
SCC: radiotherapy
Vincent GREGOIRE, MD, PhD, Hon. FRCR
Head and Neck Oncology Program, Radiation
Oncology Dept. & Center for Molecular
Imaging, Radiotherapy and Oncology,
Université Catholique de Louvain, St-Luc
University Hospital, Brussels, Belgium
EHNS-ESTRO H&N course
Florence, June 2016
Staging of oropharyngeal tumors
(TNM-UICC 2010)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma
in situ
T1 Tumor 2 cm or less in greatest dimension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension
T3 Tumor more than 4 cm in greatest dimension
T4a Tumor invades the larynx, deep/extrinsic muscle of tongue, medial
pterygoid, hard palate or mandible
T4b Tumor invades lateral pterygoid muscle, pterygoid plates, lateral
nasopharynx, or skull base or encases carotid artery
EHNS-ESTRO H&N course
Florence, June 2016